Strategic and scientific advice

Scientific advice

Our scientific advice service has helped companies reduce their NICE appraisal timeline by around 3 months.

We'll review key questions around prospective clinical trials, data collection and health economics. You’ll receive confidential technical and strategic advice from NICE, clinical, economic, health technology assessment and patient experts.

We also offer this service in partnership with the Medicines and Healthcare products Regulatory Agency or Canada’s Drug Agency.

You’ll get a 2 to 3-hour advice meeting with a tailored panel of experts and a comprehensive report detailing the discussion and recommended actions.

Companies typically use this service prior to phase 3 clinical trials or other significant studies, but you can engage with us at any point of development.

Health economic model assessment

We offer a health economic model peer review service. It’s designed for developers of pharmaceuticals and certain healthtech products.

We provide an independent, critical review and quality assessment of your economic model. You’ll get a technical report detailing model optimisation recommendations.

Companies generally use this service prior to a NICE appraisal. You’ll have completed most of your evidence generation and made a start on your economic model. 

Evidence gap analysis

Our rigorous gap analysis service helps healthtech companies refine their product’s value proposition and identify any gaps in their planned and available evidence.

You’ll get a meeting with a NICE expert and a report highlighting the main gaps and recommended actions.

We can deliver this service at any point in your evidence collection journey.